Genetic disorders are caused by alterations in the human genome and may affect almost every organ system.

More than thousands of genetic conditions have been described, ranging from relatively common inherited disorders to extremely rare diseases affecting only a small number of families.

Traditional molecular diagnostic approaches frequently involve analysis of a single gene or a limited number of variants.

Although these approaches remain useful for disorders with well-defined molecular causes, they can be inefficient when several genes can produce similar clinical manifestations.

The development of next-generation sequencing has substantially changed this diagnostic landscape.

Next-generation sequencing allows millions of DNA fragments to be analyzed simultaneously.

Depending on the selected strategy, sequencing can focus on a small group of disease-associated genes, protein-coding regions, or nearly the entire genome.

This flexibility makes NGS particularly useful for genetically heterogeneous disorders.

The application of NGS has expanded rapidly in clinical genetics because it can shorten diagnostic journeys, identify unexpected molecular causes, and support more accurate disease classification.

Principles of Next-Generation Sequencing

Next-generation sequencing involves several major steps.

DNA is first extracted from a biological sample, commonly peripheral blood, saliva, or another clinically appropriate specimen.

The DNA is then prepared into a sequencing library.

Depending on the sequencing strategy, specific genomic regions may be enriched before sequencing.

The resulting DNA fragments are sequenced in parallel.

Bioinformatic pipelines subsequently process the sequencing data.

Sequence reads are aligned to a reference genome, followed by variant identification and annotation.

Potentially pathogenic variants are then evaluated using clinical information, population databases, functional evidence, inheritance patterns, and other available evidence.

The final interpretation is generally performed using standardized variant-classification frameworks.

Major NGS Strategies

Targeted Gene Panels

Targeted sequencing panels analyze a predefined collection of genes associated with a particular disease or clinical phenotype.

For example, a panel may contain genes associated with inherited cardiomyopathy, epilepsy, hereditary cancer, or neuromuscular disease.

The focused nature of targeted panels makes data interpretation more manageable.

Sequencing depth is often high, which can improve detection of variants in targeted regions.

Panels are particularly useful when the clinical phenotype strongly suggests a specific disease group.

However, panels may fail to identify the molecular diagnosis if the responsible gene is not included.

Whole-Exome Sequencing

Whole-exome sequencing focuses primarily on protein-coding regions of the genome.

Although exons represent a relatively small proportion of the genome, they contain a substantial proportion of known disease-causing variants.

WES is therefore particularly useful for rare disorders with substantial genetic heterogeneity.

It can analyze thousands of genes simultaneously.

This makes it valuable when the clinical presentation does not clearly indicate a single genetic disorder.

WES can also facilitate discovery of unexpected molecular diagnoses.

However, WES may have limited ability to detect some structural variants, repeat expansions, deep intronic variants, and alterations in regions that are poorly captured.

Whole-Genome Sequencing

Whole-genome sequencing analyzes a much broader portion of the genome than WES.

It can provide information about coding and non-coding regions.

This broader coverage creates opportunities to identify variants that may be missed by exome sequencing.

WGS can detect many types of sequence variation, including single-nucleotide variants and small insertions or deletions.

Depending on the platform and analytical pipeline, it may also provide information about structural variation and copy-number changes.

The major challenges include the large volume of data, interpretation of non-coding variants, cost, computational requirements, and management of incidental findings.

Applications in Rare Disease Diagnosis

Rare diseases represent one of the most important applications of NGS.

Patients with rare disorders may experience a prolonged diagnostic process because symptoms overlap with numerous other conditions.

WES and WGS can simultaneously investigate many potential disease genes.

A molecular diagnosis can provide important information about prognosis, disease management, recurrence risk, and family counseling.

In some cases, identification of the molecular cause can also reveal targeted treatment opportunities.

Applications in Developmental Disorders

Developmental delay, intellectual disability, congenital anomalies, and neurodevelopmental disorders often have heterogeneous genetic causes.

NGS allows clinicians to investigate multiple candidate genes simultaneously.

Exome sequencing has become particularly useful for children with unexplained developmental disorders.

The identification of pathogenic variants can help establish a diagnosis when conventional testing has not provided an explanation.

It can also improve recognition of inherited or de novo genetic conditions.

Applications in Neurological Disorders

NGS is increasingly used in the diagnosis of inherited neurological diseases.

These include hereditary epilepsy, neuromuscular disorders, hereditary ataxias, neuropathies, and neurodegenerative conditions.

The genetic heterogeneity of these disorders makes broad sequencing particularly useful.

A molecular diagnosis may distinguish between clinically similar neurological syndromes.

It can also support family testing and reproductive counseling.

However, some neurological disorders are caused by repeat expansions or other genomic alterations that may require specialized methods beyond conventional short-read NGS.

Applications in Inherited Metabolic Disorders

Inherited metabolic disorders may result from defects in enzymes, transporters, receptors, or metabolic pathways.

Because many metabolic disorders have overlapping clinical features, genetic diagnosis can be challenging.

NGS panels and exome sequencing can simultaneously investigate numerous genes involved in metabolic pathways.

Molecular diagnosis can complement biochemical testing and may be particularly valuable when laboratory findings are inconclusive.

Applications in Hereditary Cancer Syndromes

NGS has become an important component of hereditary cancer evaluation.

Patients with strong personal or family histories of certain cancers may undergo sequencing of panels containing multiple cancer-predisposition genes.

Genes associated with hereditary breast and ovarian cancer, colorectal cancer, endocrine tumors, and other cancer syndromes can be investigated.

Identification of a pathogenic germline variant may influence surveillance strategies and family testing.

It can also contribute to treatment planning in selected clinical settings.

Applications in Cardiovascular Genetic Disorders

Inherited cardiovascular conditions can involve numerous genes.

NGS panels can investigate genes associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmia syndromes, familial hypercholesterolemia, and other inherited disorders.

A molecular diagnosis can help clarify disease etiology.

It may also support cascade testing of relatives who could benefit from appropriate clinical surveillance.

Applications in Prenatal and Reproductive Genetics

NGS is increasingly being investigated and applied in prenatal diagnosis.

Sequencing may be considered when fetal abnormalities are identified and conventional genetic testing has not established a diagnosis.

Exome sequencing can be useful in selected cases of fetal structural anomalies.

Carrier screening can also use sequencing-based approaches to evaluate multiple genes simultaneously.

However, prenatal genomic testing requires careful counseling because results can create complex medical, ethical, and reproductive decisions.

Figure 1. Clinical Workflow of Next-Generation Sequencing

                 PATIENT

                    │

                    ▼

             Clinical Evaluation

                    │

                    ▼

              Sample Collection

                    │

                    ▼

               DNA Extraction

                    │

                    ▼

          ┌─────────┴─────────┐

          ▼                   ▼

     Targeted Panel          WES / WGS

          │                   │

          └─────────┬─────────┘

                    ▼

                Sequencing

                    │

                    ▼

          Bioinformatic Analysis

                    │

                    ▼

              Variant Calling

                    │

                    ▼

          Variant Classification

                    │

        ┌───────────┼───────────┐

        ▼           ▼           ▼

    Pathogenic    VUS       Benign/Likely

        │                       │

        ▼                       ▼

 Clinical Diagnosis       No Molecular Diagnosis

        │

        ▼

 Genetic Counseling &

 Personalized Management

Figure 1: General workflow illustrating the major steps involved in applying next-generation sequencing to the diagnosis of genetic disorders.

Variant Interpretation

Identifying a genetic variant does not automatically establish a diagnosis.

Variants must be interpreted according to available evidence.

Important considerations include population frequency, predicted molecular consequences, previous disease associations, functional studies, segregation within families, and phenotype compatibility.

Variants are commonly classified into categories such as pathogenic, likely pathogenic, uncertain significance, likely benign, and benign.

Variants of uncertain significance represent a major challenge.

A VUS should generally not be treated as equivalent to a pathogenic variant.

Additional family studies and functional investigations may eventually provide evidence allowing reclassification.

Review Design

The present article was prepared as a narrative review examining applications of next-generation sequencing in the diagnosis of genetic disorders.

Literature Search

Relevant scientific literature was considered from major biomedical databases and peer-reviewed journals.

Search terms included combinations of “next-generation sequencing,” “genetic disorders,” “whole-exome sequencing,” “whole-genome sequencing,” “targeted sequencing,” “rare disease diagnosis,” “variant interpretation,” “clinical genomics,” and “genetic testing.”

Inclusion Criteria

Studies addressing clinical applications of NGS, diagnostic yield, variant identification, genetic disease diagnosis, sequencing strategies, and clinical interpretation were considered relevant.

Data Synthesis

The literature was organized according to sequencing strategies, diagnostic applications, variant interpretation, clinical benefits, limitations, and future directions.

Results

The reviewed evidence demonstrates that NGS has substantially expanded the ability to identify genetic causes of disease.

Targeted panels provide efficient analysis of predefined groups of disease-associated genes.

WES is particularly valuable for rare and genetically heterogeneous disorders.

WGS provides broader genomic coverage and may identify variants outside protein-coding regions.

NGS applications have expanded across rare diseases, developmental disorders, neurological disorders, inherited metabolic conditions, hereditary cancer syndromes, cardiovascular diseases, and selected prenatal conditions.

The diagnostic value of NGS is highest when sequencing results are interpreted together with detailed clinical information

NGS has transformed genetic diagnosis by changing the scale at which the human genome can be investigated.

Traditional genetic testing often required a sequential approach.

A clinician would test one gene, and if the result was negative, another gene would be investigated.

This process could be expensive and time-consuming when several genes were associated with the same phenotype.

NGS allows multiple genes to be investigated simultaneously.

This is particularly valuable for disorders with extensive genetic heterogeneity.

Rare diseases illustrate this advantage clearly.

Patients with unusual clinical presentations may undergo years of diagnostic investigations before a molecular cause is identified.

Exome or genome sequencing can potentially shorten this diagnostic pathway by examining a large number of candidate genes at once.

Another important advantage is the ability to identify unexpected diagnoses.

A patient's phenotype may resemble one disorder, while sequencing reveals a pathogenic variant associated with a different condition.

This can improve disease classification and sometimes alter clinical management.

Nevertheless, NGS does not eliminate diagnostic uncertainty.

A major challenge is variant interpretation.

Modern sequencing can identify thousands of genetic differences in an individual.

Most are benign or have no established clinical significance.

Distinguishing clinically relevant variants from harmless variation requires sophisticated bioinformatic and clinical interpretation.

Variants of uncertain significance remain particularly challenging.

As additional research becomes available, some VUSs may eventually be reclassified.

Another limitation involves technical detection.

Short-read sequencing can be less effective for certain repeat expansions, complex structural variants, repetitive genomic regions, and some deep intronic alterations.

Therefore, a negative NGS result does not necessarily exclude a genetic disorder.

Other methods may be required depending on the suspected disease.

Comparison of Major Sequencing Approaches

Clinical Advantages

NGS provides several important clinical advantages.

It can improve diagnostic efficiency by evaluating many genes simultaneously.

It can identify unexpected molecular diagnoses.

It may reduce the number of sequential genetic tests.

It can support family-based testing and genetic counseling.

In selected disorders, identifying a pathogenic variant can directly influence clinical management.

NGS may also facilitate the recognition of inherited conditions in relatives who have not yet developed symptoms.

Limitations and Challenges

Despite its advantages, several limitations remain.

The interpretation of variants can be difficult.

Sequencing may identify incidental findings unrelated to the original clinical question.

Data storage and computational analysis require substantial infrastructure.

Some genomic alterations remain difficult to detect using standard short-read sequencing.

Differences in reference populations can affect variant interpretation.

Access to clinical genomic testing is also unequal across healthcare systems.

Genetic counseling is therefore an important component of responsible NGS implementation.

Ethical Considerations

Genomic sequencing can reveal information about both patients and their biological relatives.

Patients may receive unexpected information about disease susceptibility, carrier status, or inherited conditions.

Incidental findings can create difficult clinical and ethical decisions.

Privacy and secure handling of genomic information are essential.

Pre-test and post-test genetic counseling can help patients understand the possible outcomes of sequencing.

Appropriate consent should address the scope of testing and the possibility of identifying findings unrelated to the original diagnostic question.

Future Perspectives

Future developments in sequencing technology are expected to improve diagnostic accuracy.

Long-read sequencing may improve detection of structural variants, repeat expansions, and complex genomic regions.

Integration of genomic sequencing with transcriptomics may help determine whether variants alter gene expression or RNA splicing.

Artificial intelligence and advanced computational tools may improve variant prioritization and interpretation.

Multi-omics approaches may provide additional biological evidence for variants that are currently classified as uncertain.

The integration of genomic data with electronic health records may also support more efficient clinical interpretation.

As reference databases become increasingly diverse, variant interpretation should become more accurate across different populations.

Next-generation sequencing has become a fundamental technology in modern genetic diagnosis.

Targeted panels, whole-exome sequencing, and whole-genome sequencing provide complementary approaches for investigating genetic disorders.

NGS is particularly valuable for rare diseases, developmental disorders, inherited metabolic conditions, neurological disorders, hereditary cancers, cardiovascular diseases, and selected prenatal cases.

Its greatest strength is the ability to investigate large numbers of genes simultaneously.

However, sequencing results must be interpreted carefully because the detection of a variant does not necessarily establish pathogenicity.

Technical limitations, variants of uncertain significance, incidental findings, ethical considerations, and unequal access remain important challenges.

Future advances in long-read sequencing, artificial intelligence, multi-omics, and clinical decision-support systems are likely to further improve genomic diagnosis.

The continued integration of NGS with detailed clinical evaluation and genetic counseling will support more accurate diagnosis and increasingly personalized management of genetic disorders.

1. Metzker ML. Emerging technologies in DNA sequencing. Genome Research. 2010;20:1051–1066.
2. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genetics in Medicine. 2013;15:733–747.
3. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants. Genetics in Medicine. 2015;17:405–424.
4. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291.
5. Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing. Nature Reviews Genetics. 2013;14:681–691.
6. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. New England Journal of Medicine. 2014;370:2418–2425.
7. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. New England Journal of Medicine. 2013;369:1502–1511.
8. Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–1879.
9. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-genome sequencing across clinical indications. Genetics in Medicine. 2016;18:696–704.
10. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nature Reviews Genetics. 2018;19:253–268.
11. Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing. Genetics in Medicine. 2023;25:1003–1011.
12. Manolio TA, Rowley R, Williams MS, et al. Opportunities, resources, and techniques for implementing genomics in clinical care. Nature Genetics. 2018;50:1112–1121.
13. Stark Z, Tan TY, Chong B, et al. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genetics in Medicine. 2016;18:1090–1096.
14. Posey JE. Genome sequencing and implications for rare disorders. Nature Reviews Genetics. 2019;20:81–98.
15. Genovese G, Fromer M, Stahl EA, et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nature Neuroscience. 2016;19:1433–1441.
16. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nature Reviews Genetics. 2016;17:333–351.
17. Levy-Sakin M, Ebenstein Y. Beyond sequencing: next-generation technologies for the future of genomic research. Genome Biology. 2013;14:201.
18. van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends in Genetics. 2014;30:418–426.
19. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469–476.
20. Wright CF, McRae JF, Clayton S, et al. Making new genetic diagnoses with new genomic technologies. New England Journal of Medicine. 2018;379:1157–1168.